{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:56:34Z","timestamp":1791212194005,"version":"4.1.0"},"reference-count":259,"publisher":"National Institute for Health and Care Research","issue":"9","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["13\/46\/01"],"award-info":[{"award-number":["13\/46\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title><jats:p>Tumour necrosis factor (TNF)-\u03b1 inhibitors (anti-TNFs) are typically used when the inflammatory rheumatologic diseases ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-AxSpA) have not responded adequately to conventional therapy. Current National Institute for Health and Care Excellence (NICE) guidance recommends treatment with adalimumab, etanercept and golimumab in adults with active (severe) AS only if certain criteria are fulfilled but it does not recommend infliximab for AS. Anti-TNFs for patients with nr-AxSpA have not previously been appraised by NICE.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-2\"><jats:title>Objective<\/jats:title><jats:p>To determine the clinical effectiveness, safety and cost-effectiveness within the NHS of adalimumab, certolizumab pegol, etanercept, golimumab and infliximab, within their licensed indications, for the treatment of severe active AS or severe nr-AxSpA (but with objective signs of inflammation).<\/jats:p><\/jats:sec><jats:sec id=\"abs1-3\"><jats:title>Design<\/jats:title><jats:p>Systematic review and economic model.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-4\"><jats:title>Data sources<\/jats:title><jats:p>Fifteen databases were searched for relevant studies in July 2014.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-5\"><jats:title>Review methods<\/jats:title><jats:p>Clinical effectiveness data from randomised controlled trials (RCTs) were synthesised using Bayesian network meta-analysis methods. Results from other studies were summarised narratively. Only full economic evaluations that compared two or more options and considered both costs and consequences were included in the systematic review of cost-effectiveness studies. The differences in the approaches and assumptions used across the studies, and also those in the manufacturer\u2019s submissions, were examined in order to explain any discrepancies in the findings and to identify key areas of uncertainty. A de novo decision model was developed with a generalised framework for evidence synthesis that pooled change in disease activity (BASDAI and BASDAI 50) and simultaneously synthesised information on function (BASFI) to determine the long-term quality-adjusted life-year and cost burden of the disease in the economic model. The decision model was developed in accordance with the NICE reference case. The model has a lifetime horizon (60 years) and considers costs from the perspective of the NHS and personal social services. Health effects were expressed in terms of quality-adjusted life-years.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-6\"><jats:title>Results<\/jats:title><jats:p>In total, 28 eligible RCTs were identified and 26 were placebo controlled (mostly up to 12 weeks); 17 extended into open-label active treatment-only phases. Most RCTs were judged to have a low risk of bias overall. In both AS and nr-AxSpA populations, anti-TNFs produced clinically important benefits to patients in terms of improving function and reducing disease activity; for AS, the relative risks for ASAS 40 ranged from 2.53 to 3.42. The efficacy estimates were consistently slightly smaller for nr-AxSpA than for AS. Statistical (and clinical) heterogeneity was more apparent in the nr-AxSpA analyses than in the AS analyses; both the reliability of the nr-AxSpA meta-analysis results and their true relevance to patients seen in clinical practice are questionable. In AS, anti-TNFs are approximately equally effective. Effectiveness appears to be maintained over time, with around 50% of patients still responding at 2 years. Evidence for an effect of anti-TNFs delaying disease progression was limited; results from ongoing long-term studies should help to clarify this issue. Sequential treatment with anti-TNFs can be worthwhile but the drug survival response rates and benefits are reduced with second and third anti-TNFs. The de novo model, which addressed many of the issues of earlier evaluations, generated incremental cost-effectiveness ratios ranging from \u00a319,240 to \u00a366,529 depending on anti-TNF and modelling assumptions.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-7\"><jats:title>Conclusions<\/jats:title><jats:p>In both AS and nr-AxSpA populations anti-TNFs are clinically effective, although more so in AS than in nr-AxSpA. Anti-TNFs may be an effective use of NHS resources depending on which assumptions are considered appropriate.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-8\"><jats:title>Future work recommendations<\/jats:title><jats:p>Randomised trials are needed to identify the nr-AxSpA population who will benefit the most from anti-TNFs.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-9\"><jats:title>Study registration<\/jats:title><jats:p>This study is registered as PROSPERO CRD42014010182.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-10\"><jats:title>Funding<\/jats:title><jats:p>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta20090","type":"journal-article","created":{"date-parts":[[2016,2,10]],"date-time":"2016-02-10T09:02:42Z","timestamp":1455094962000},"page":"1-334","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":66,"title":["Tumour necrosis factor-\u03b1 inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"20","author":[{"given":"Mark","family":"Corbett","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Soares","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurleen","family":"Jhuti","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Rice","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldon","family":"Spackman","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Sideris","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirimon","family":"Moe-Byrne","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Fox","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"Division of Rheumatic and Musculoskeletal Disease, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Kay","sequence":"additional","affiliation":[{"name":"Division of Rheumatic and Musculoskeletal Disease, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerys","family":"Woolacott","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,2]]},"reference":[{"key":"key20160205101913341_ref1-bib1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/ijr.12.61","article-title":"The new ASAS classification criteria for axial and peripheral spondyloarthritis","volume":"7","author":"Lipton","year":"2012","journal-title":"Int J Clin Rheumatol"},{"key":"key20160205101913341_ref1-bib2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic-criteria for ankylosing-spondylitis \u2013 a proposal for modification of the New York criteria","volume":"27","author":"Vanderlinden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1756-185X.2012.01765.x","article-title":"Update on biologic therapies in ankylosing spondylitis: a literature review","volume":"15","author":"Goh","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"key20160205101913341_ref1-bib6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/annrheumdis-2012-202073","article-title":"Viewpoint axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis","volume":"72","author":"Robinson","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrrheum.2012.33","article-title":"Diagnosis and classification in spondyloarthritis: identifying a chameleon","volume":"8","author":"van Tubergen","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"key20160205101913341_ref1-bib8","volume-title":"Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis","author":"Deodhar","year":"2014"},{"key":"key20160205101913341_ref1-bib9","volume-title":"National Ankylosing Spondylitis Society (NASS) Website","author":"National Ankylosing Spondylitis Society"},{"key":"key20160205101913341_ref1-bib10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/ard.2008.091793","article-title":"Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"key20160205101913341_ref1-bib12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3899\/jrheum.080871","article-title":"The natural course of radiographic progression in ankylosing spondylitis \u2013 evidence for major individual variations in a large proportion of patients","volume":"36","author":"Baraliakos","year":"2009","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3899\/jrheum.090899","article-title":"Disease severity in ankylosing spondylitis: variation by region and local area deprivation","volume":"37","author":"Healey","year":"2010","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10067-012-2092-3","article-title":"Patients with well-established ankylosing spondylitis show limited deterioration in a ten-year prospective cohort study","volume":"32","author":"Healey","year":"2013","journal-title":"Clin Rheumatol"},{"key":"key20160205101913341_ref1-bib15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib16","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","article-title":"Increased mortality in ankylosing spondylitis is related to disease activity","volume":"70","author":"Bakland","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib17","volume-title":"Technology Appraisal TA143: Ankylosing Spondylitis \u2013 Adalimumab, Etanercept and Infliximab","author":"National Institute for Health and Care Excellence","year":"2008"},{"key":"key20160205101913341_ref1-bib18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis results from the German Spondyloarthritis Inception Cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ng.513","article-title":"Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci","volume":"42","author":"Reveille","year":"2010","journal-title":"Nat Genet"},{"key":"key20160205101913341_ref1-bib20","volume-title":"Ankylosing Spondylitis","author":"NHS Choices"},{"key":"key20160205101913341_ref1-bib21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","article-title":"The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States","volume":"345","author":"Reveille","year":"2013","journal-title":"Am J Med Sci"},{"key":"key20160205101913341_ref1-bib22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.37803","article-title":"Review: nonradiographic axial spondyloarthritis: new definition of an old disease?","volume":"65","author":"Sieper","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib23","volume-title":"Ankylosing Spondylitis: Prevalence","author":"National Institute for Health and Care Excellence"},{"key":"key20160205101913341_ref1-bib24","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/ard.2011.150037","article-title":"A stratified model for health outcomes in ankylosing spondylitis","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib25","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/art.20446","article-title":"What is the most appropriate radiologic scoring method for ankylosing spondylitis?","volume":"50","author":"Wanders","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0895-4356(01)00496-6","article-title":"What are the main methodological problems in the estimation of placebo effects?","volume":"55","author":"Hr\u00f3bjartsson","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"key20160205101913341_ref1-bib27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/0272989X10362106","article-title":"Cost-effectiveness analysis: discount the placebo at your peril","volume":"30","author":"Hawkins","year":"2010","journal-title":"Med Decis Making"},{"key":"key20160205101913341_ref1-bib28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/rheumatology\/kep435","article-title":"Frequency and characteristics of disease flares in ankylosing spondylitis","volume":"49","author":"Cooksey","year":"2010","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib29","doi-asserted-by":"publisher","first-page":"CD003974","DOI":"10.1002\/14651858.cd003974.pub3","article-title":"Placebo interventions for all clinical conditions","volume":"1","author":"Hr\u00f3bjartsson","year":"2010","journal-title":"Cochrane Database Sys Rev"},{"key":"key20160205101913341_ref1-bib30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib31","doi-asserted-by":"publisher","first-page":"CD002822","DOI":"10.1002\/14651858.cd002822.pub3","article-title":"Physiotherapy interventions for ankylosing spondylitis","volume":"1","author":"Dagfinrud","year":"2008","journal-title":"Cochrane Database Sys Rev"},{"key":"key20160205101913341_ref1-bib32","volume-title":"Looking Ahead: Best Practice for the Care of People with Ankylosing Spondylitis (AS)","author":"National Ankylosing Spondylitis Society (NASS)","year":"2013"},{"key":"key20160205101913341_ref1-bib33","volume-title":"Technology Appraisal TA233: Ankylosing Spondylitis \u2013 Golimumab","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"key20160205101913341_ref1-bib34","volume-title":"National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal: TNF-alpha Inhibitors for Severe Active Ankylosing Spondylitis and Severe Axial Spondyloarthritis without Radiographic Evidence of Ankylosing Spondylitis","author":"AbbVie"},{"key":"key20160205101913341_ref1-bib35","volume-title":"National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal: Certolizumab Pegol for the Treatment of Ankylosing Spondylitis and Axial Spondyloarthritis without Radiographic Evidence of Ankylosing Spondylitis. Submission by UCB, manufacturer of certolizumab pegol, September 2014","author":"UCB"},{"key":"key20160205101913341_ref1-bib36","volume-title":"National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal: Ankylosing Spondylitis and Axial Spondyloarthritis (Non-radiographic) \u2013 Adalimumab, Etanercept Infliximab and Golimumab","author":"Pfizer"},{"key":"key20160205101913341_ref1-bib37","volume-title":"National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal: TNF-alpha Inhibitors for Ankylosing Spondylitis and Axial Spondyloarthritis without Radiographic Evidence of Ankylosing Spondylitis (Including a Review of TA143 and TA233)","author":"Merck Sharp & Dohme"},{"issue":"28","key":"key20160205101913341_ref1-bib38","doi-asserted-by":"publisher","DOI":"10.3310\/hta11280","article-title":"Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation","volume":"11","author":"McLeod","year":"2007","journal-title":"Health Technol Assess"},{"key":"key20160205101913341_ref1-bib39","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key20160205101913341_ref1-bib40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"JRSM"},{"key":"key20160205101913341_ref1-bib41","doi-asserted-by":"crossref","unstructured":"Pedersen SJ, Sorensen IJ, Loft AG, Hindrup JS, Thamsborg G, Asmussen K, et al. Efficacy of Adalimumab in Patients with Axial Spondyloarthritis: Results of an Investigator-Initiated 12-Weeks Randomized Double-Blind Placebo Controlled Trial with a 12 Weeks Open-Label Extension Phase. Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR, Madrid, 12\u201315 June 2013.","DOI":"10.1136\/annrheumdis-2013-eular.894"},{"key":"key20160205101913341_ref1-bib42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s13075-014-0481-5","article-title":"Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study","volume":"16","author":"Dougados","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"key20160205101913341_ref1-bib44","volume-title":"Danish Multicenter Study of Adalimumab in Spondyloarthritis","author":"ClinicalTrials.gov"},{"key":"key20160205101913341_ref1-bib45","volume-title":"Effect of Golimumab in Participants with Active Axial Spondyloarthritis (P07642 AM2)","author":"ClinicalTrials.gov"},{"key":"key20160205101913341_ref1-bib46","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib47","first-page":"151","article-title":"A multicenter, double-blind, placebo-controlled, randomized III clinical study of etanercept in the treatment of Chinese subjects with active ankylosing spondylitis","volume":"13","author":"Zhang","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"key20160205101913341_ref1-bib48","first-page":"1846","article-title":"Efficacy of etanercept in patients with ankylosing spondylitis: a double-blind, randomized, placebo controlled trial","volume":"18","author":"Zhang","year":"2009","journal-title":"Chin J New Drugs"},{"key":"key20160205101913341_ref1-bib49","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib50","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib51","first-page":"745","article-title":"A randomized controlled trial of infliximab shows clinical and MRI efficacy in HLA B27 positive very early ankylosing spondylitis","volume":"26","author":"Barkham","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib52","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib53","first-page":"i52","article-title":"Adalimumab is effective in patients with preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial","volume":"46","author":"Haibel","year":"2007","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib54","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial","volume":"54","author":"Haibel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1756-185X.2012.01734.x","article-title":"Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis","volume":"15","author":"Hu","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"key20160205101913341_ref1-bib56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib57","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/art.23044","article-title":"Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study","volume":"56","author":"Lambert","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib58","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib59","doi-asserted-by":"publisher","first-page":"2486A","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis results from a phase 3 study","volume":"63","author":"Sieper","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib60","first-page":"1312","article-title":"Effect of adalimumab on function, health-related quality of life, work productivity, and daily activities in patients with non-radiographic axial spondyloarthritis","volume":"63","author":"Maksymowych","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib61","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib62","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/art.22887","article-title":"Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study","volume":"57","author":"Davis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib63","first-page":"S208","article-title":"Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: the ATLAS trial","volume":"52","author":"Davis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landewe","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib65","doi-asserted-by":"publisher","first-page":"A515","DOI":"10.1136\/annrheumdis-2013-eular.1546","article-title":"Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of rapid-axSpA study","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib66","doi-asserted-by":"publisher","first-page":"A287","DOI":"10.1136\/annrheumdis-2013-eular.888","article-title":"Rapid improvements in patient-reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis: 24-week results of rapid-axSpA study","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib67","doi-asserted-by":"publisher","first-page":"A86","DOI":"10.1136\/annrheumdis-2013-eular.311","article-title":"Effect of certolizumab pegol on signs and symptoms of axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24-week results of rapid-axSpA study","volume":"72","author":"Landewe","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib68","doi-asserted-by":"publisher","first-page":"A227","DOI":"10.1016\/j.jval.2013.03.1150","article-title":"Rapid improvements in patient-reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24-week results of a phase 3 double blind randomized placebo-controlled study","volume":"16","author":"Sieper","year":"2013","journal-title":"Value Health"},{"key":"key20160205101913341_ref1-bib69","first-page":"S336","article-title":"Effect of certolizumab pegol on signs and symptoms of ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study","volume":"64","author":"Landewe","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib70","first-page":"S243","article-title":"Rapid improvements in patient reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study","volume":"64","author":"Sieper","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib71","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2009.121327","article-title":"Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis","volume":"69","author":"Barkham","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib72","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib73","first-page":"65","article-title":"Etanercept (Enbrel\u00ae) improves signs and symptoms of ankylosing spondylitis: Results of a phase 3 multicenter clinical trial","volume":"62","author":"Davis","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib74","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib75","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis. Results of a randomized double blind placebo-controlled study (SPINE)","volume":"60","author":"Dougados","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib76","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib77","doi-asserted-by":"publisher","first-page":"A87","DOI":"10.1136\/annrheumdis-2013-eular.313","article-title":"Clinical and imaging efficacy of etanercept in early non-radiographic axial spondyloarthritis: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib78","first-page":"S656","article-title":"Patient-reported outcomes of etanercept in early non-radiographic axial spondyloarthritis: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Dougados","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib79","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"key20160205101913341_ref1-bib80","first-page":"2947","article-title":"Efficacy of etanercept (Enbrel\u00ae) in the treatment of ankylosing spondylitis: a randomized, placebo-controlled, double-blind study","volume":"44","author":"Gorman","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib81","first-page":"S90","article-title":"A randomized, double-blind, placebo-controlled trial of (Enbrel\u00ae) in the treatment of ankylosing spondylitis","volume":"44","author":"Gorman","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib82","first-page":"S403","article-title":"Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study","volume":"43","author":"Gorman","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib83","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib84","first-page":"S172","article-title":"Assessments of disease activity and functionality by Enbrel-treated ankylosing spondylitis patients in a multicenter, placebo-controlled trial","volume":"48","author":"Calin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib85","first-page":"95","article-title":"A multicentre, placebo-controlled trial of enbrel in ankylosing spondylitis","volume":"62","author":"Calin","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib86","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50\u2009mg once weekly is as effective as 25\u2009mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"van der Heijde","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib87","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","article-title":"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50\u2009mg once-weekly and 25\u2009mg twice-weekly","volume":"46","author":"Braun","year":"2007","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib88","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","article-title":"A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis","volume":"30","author":"Giardina","year":"2010","journal-title":"Rheumatol Int"},{"key":"key20160205101913341_ref1-bib89","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00296-009-1157-3","article-title":"Infliximab and etanercept are both effective and safe in patients with ankylosing spondylitis. A two-year randomised study","volume":"66","author":"Impastato","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib90","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib91","first-page":"A56","article-title":"Golimumab, a new, human, TNFA antibody, in ankylosing spondylitis: 24-week efficacy and safety results of the golimumab, a new, human, a antibody, in ankylosing spondylitis: 24-week efficacy and safety results of the GO-RAISE study","volume":"39","author":"Braun","year":"2009","journal-title":"Intern Med J"},{"key":"key20160205101913341_ref1-bib92","first-page":"i57","article-title":"Golimumab, a new, human, TNFalpha antibody, in ankylosing spondylitis (AS): 24-week efficacy and safety results of the go-raise study","volume":"48","author":"Braun","year":"2009","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib93","first-page":"747","article-title":"Golimumab, a new, human, TNF-alpha antibody administered subcutaneously every 4 weeks, in ankylosing spondylitis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study","volume":"26","author":"Braun","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib94","first-page":"4236","article-title":"Golimumab, a new, human, TNF-alpha antibody administered as a monthly subcutaneous injection in ankylosing spondylitis (AS): 24-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study","volume":"56","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib95","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao","year":"2014","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib96","first-page":"S589","article-title":"Golimumab administered subcutaneously every 4 weeks in Chinese patients with active ankylosing spondylitis: week 24 safety and efficacy results from a randomized, placebo-controlled study","volume":"64","author":"Bao","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib97","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/rheumatology\/ket469","article-title":"The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis \u2013 a randomized, placebo-controlled pilot trial","volume":"53","author":"Tam","year":"2014","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib98","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"key20160205101913341_ref1-bib99","first-page":"S89","article-title":"Quality of life improvement in patients with severe ankylosing spondylitis upon treatment with the anti-TNF alpha antibody infliximab in a placebo controlled multicenter trial","volume":"44","author":"Brandt","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib100","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib101","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib102","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib103","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib104","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.22097","article-title":"Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial","volume":"55","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib105","first-page":"317","article-title":"The effect of infliximab therapy on spinal inflammation assessed by magnetic resonance imaging in a randomized, placebo-controlled trial of 279 patients with ankylosing spondylitis","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib106","first-page":"318","article-title":"Infliximab improves fatigue and pain in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib107","first-page":"402","article-title":"Efficacy of infliximab in subgroups of patients with ankylosing spondylitis: results from the ankylosing spondylitis study for the evaluation of recombinant infliximab therapy (ASSERT)","volume":"63","author":"Braun","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib108","first-page":"402","article-title":"Infliximab improves quality of life in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"63","author":"Braun","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib109","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a 24-week randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib110","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib111","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2012-eular.1850","article-title":"A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis","volume":"71","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib112","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumor necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib113","first-page":"80","article-title":"Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study","volume":"32","author":"Pavy","year":"2005","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib114","volume-title":"Summary Minutes of the Arthritis Advisory Committee Meeting July 23, 2013","author":"US Food and Drug Administration (FDA)","year":"2013"},{"key":"key20160205101913341_ref1-bib115","volume-title":"FDA Briefing Package: sBLA 125160\/215: Cimzia\u00ae (Certolizumab) for the Treatment of Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis","author":"US Food and Drug Administration (FDA)","year":"2013"},{"key":"key20160205101913341_ref1-bib116","volume-title":"FDA Briefing Package: sBLA 125057\/323: Adalimumab for the Treatment of Active Non-Radiographic Axial Spondyloarthritis in Adults with Objective Signs of Inflammation by Elevated C-reactive Protein (CRP) or Magnetic Resonance Imaging (MRI), Who Have Had an Inadequate Response to, or are Intolerant to, a Nonsteroidal Anti-Inflammatory Drug","author":"US Food and Drug Administration (FDA)","year":"2013"},{"key":"key20160205101913341_ref1-bib117","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key20160205101913341_ref1-bib118","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.62.8.732","article-title":"Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries","volume":"62","author":"Boonen","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib119","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib120","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib121","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib122","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib123","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","article-title":"Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab","volume":"46","author":"Baraliakos","year":"2007","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib124","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib125","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/annrheumdis-2013-eular.1973","article-title":"Evolution of radiographic damage in ankylosing spondylitis over 12 years of follow-up","volume":"72","author":"Ramiro","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib126","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"key":"key20160205101913341_ref1-bib127","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2012-eular.849","article-title":"Retention rate of adalimumab, etanercept and infliximab at 5 years in patients with ankylosing spondylitis: report from the rhumadata computerized database","volume":"71","author":"Choquette","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib128","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3109\/03009742.2014.918173","article-title":"Efficacy and drug survival of anti-tumor necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden","volume":"43","author":"Gulfe","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"key20160205101913341_ref1-bib129","doi-asserted-by":"publisher","first-page":"867","DOI":"10.5414\/CP201707","article-title":"The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 \u2013 a retrospective analysis","volume":"50","author":"Nell-Duxneuner","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key20160205101913341_ref1-bib130","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12325-014-0110-3","article-title":"Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample","volume":"31","author":"Yeaw","year":"2014","journal-title":"Adv Ther"},{"key":"key20160205101913341_ref1-bib131","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scire","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib132","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-014-3094-z","article-title":"Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria","volume":"35","author":"Zufferey","year":"2014","journal-title":"Rheumatol Int"},{"key":"key20160205101913341_ref1-bib133","first-page":"958","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib134","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib135","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib136","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib137","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.cd008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160205101913341_ref1-bib138","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"key20160205101913341_ref1-bib139","doi-asserted-by":"publisher","DOI":"10.3310\/hta15100","article-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","volume":"15","author":"Rodgers","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20160205101913341_ref1-bib140","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib141","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib142","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/ard.2011.154799","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib143","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib144","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib145","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib146","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","article-title":"Etanercept in the longterm treatment of patients with ankylosing spondylitis","volume":"36","author":"Dijkmans","year":"2009","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib147","first-page":"238","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Martin-Mola","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib148","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years \u2013 early clinical response predicts long-term outcome","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib149","unstructured":"Dean LE, Macfarlane GJ, MacDonald AG. The Natural History of Ankylosing Spondylitis \u2013 Results from the Scotland and Ireland Registry for Ankylosing Spondylitis (SIRAS). British Society for Rheumatology Annual Scientific Meeting. Liverpool: University of Aberdeen; 2013."},{"key":"key20160205101913341_ref1-bib150","first-page":"410","article-title":"Longitudinal analyses of disease outcomes in ankylosing spondylitis yield insight into the natural history of AS","volume":"66","author":"Stone","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib151","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib152","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/rheumatology\/keh271","article-title":"The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade\u00ae)","volume":"43","author":"Kobelt","year":"2004","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib153","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res"},{"key":"key20160205101913341_ref1-bib154","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","article-title":"Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib155","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib156","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/rheumatology\/ken176","article-title":"Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration","volume":"47","author":"Stone","year":"2008","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib157","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3899\/jrheum.090625","article-title":"Undifferentiated spondyloarthritis: a longterm followup","volume":"37","author":"Sampaio-Barros","year":"2010","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib158","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s100670170066","article-title":"Undifferentiated spondyloarthropathies: a 2-year follow-up study","volume":"20","author":"Sampaio-Barros","year":"2001","journal-title":"Clin Rheumatol"},{"key":"key20160205101913341_ref1-bib159","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","article-title":"The burden of non-radiographic axial spondyloarthritis","volume":"44","author":"Boonen","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib160","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1017\/S0266462307070432","article-title":"Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials","volume":"23","author":"Kobelt","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"key20160205101913341_ref1-bib161","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/rheumatology\/kem133","article-title":"The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK","volume":"46","author":"Ara","year":"2007","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib162","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/rheumatology\/kem031","article-title":"Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom","volume":"46","author":"Botteman","year":"2007","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib163","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40273-013-0049-2","article-title":"Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal","volume":"31","author":"Armstrong","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"key20160205101913341_ref1-bib164","volume-title":"Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients who do not Have X-ray Structural Changes (AS EARLY)","author":"ClinicalTrials.gov"},{"key":"key20160205101913341_ref1-bib165","volume-title":"Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis","author":"ClinicalTrials.gov"},{"key":"key20160205101913341_ref1-bib166","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/ard.2004.025130","article-title":"Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis","volume":"64","author":"Braun","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib167","first-page":"273","article-title":"The direct healthcare resource costs associated with ankylosing spondylitis patients attending a UK secondary care rheumatology unit","volume":"65","author":"Ara","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib168","first-page":"246","article-title":"Healthcare costs and productivity losses directly attributable to ankylosing spondylitis","volume":"30","author":"Rafia","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib169","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/rheumatology\/keh669","article-title":"BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology","volume":"44","author":"Keat","year":"2005","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib170","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Ser B"},{"key":"key20160205101913341_ref1-bib171","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/hec.1797","article-title":"Research decisions in the face of heterogeneity: what can a new study tell us?","volume":"21","author":"Welton","year":"2012","journal-title":"Health Econ"},{"key":"key20160205101913341_ref1-bib172","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib173","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","article-title":"Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Lord","year":"2010","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib174","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity \u2013 subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"key20160205101913341_ref1-bib175","volume-title":"Technology Appraisal TA199: Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key20160205101913341_ref1-bib176","volume-title":"NHS Reference Costs 2012\/13","author":"Department of Health","year":"2013"},{"key":"key20160205101913341_ref1-bib177","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/annrheumdis-2014-eular.3599","article-title":"Patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis demonstrate the same clinical disease course over two years: results from the GESPIC cohort","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib178","volume-title":"British National Formulary (Online)","author":"Joint Formulary Committee"},{"key":"key20160205101913341_ref1-bib179","volume-title":"Unit Costs of Health and Social Care 2013","author":"Curtis","year":"2013"},{"key":"key20160205101913341_ref1-bib180","doi-asserted-by":"publisher","first-page":"b5606","DOI":"10.1136\/bmj.b5606","article-title":"Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery","volume":"340","author":"Henriksson","year":"2010","journal-title":"BMJ"},{"key":"key20160205101913341_ref1-bib181","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7861\/clinmedicine.12-4-324","article-title":"Compliance with NICE guidance on the use of anti-TNF alpha agents in ankylosing spondylitis: an east and west Midlands regional audit","volume":"12","author":"Rees","year":"2012","journal-title":"Clin Med"},{"key":"key20160205101913341_ref1-bib182","volume-title":"Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis with Low Disease Activity (SPACING)","author":"University Hospital Montpellier","year":"2012"},{"key":"key20160205101913341_ref1-bib183","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"key20160205101913341_ref1-bib184","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"key20160205101913341_ref1-bib185","first-page":"1798","article-title":"No progression of chronic sacroiliac changes in patients with active, non-radiographic axial spondyloarthritis treated with adalimumab over 52 weeks","volume":"60","author":"Haibel","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib186","first-page":"iI80","article-title":"Adalimumab is effective in patients with preradiographic axial spondyloarthritis (PRSPA): results of a 12-week, randomised controlled trial with a 40-week open-label extension (OLE)","volume":"47","author":"Haibel","year":"2008","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib187","first-page":"14","article-title":"Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 20-week, randomized controlled trial with an open-label extension phase","volume":"66","author":"Haibel","year":"2007","journal-title":"Z Rheumatol"},{"key":"key20160205101913341_ref1-bib188","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of preiradiographic axial spondyloarthritis: results of a 20-week, randomized controlled trial with an open-label extension phase","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib189","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/annrheumdis-2013-eular.889","article-title":"Relationship between MRI and clinical remission in patients with non-radiographic axial spondyloarthritis after two years of adalimumab therapy","volume":"72","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib190","doi-asserted-by":"publisher","first-page":"i140","DOI":"10.1136\/annrheumdis-2013-eular.314","article-title":"Sustained clinical remission in patients with non-radiographic axial spondyloarthritis after two years of adalimumab treatment","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib191","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/annrheumdis-2012-eular.2240","article-title":"Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis: week 68 results from ability 1","volume":"71","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib192","first-page":"S1052","article-title":"Improvement in physical function, health-related quality of life, and work productivity with adalimumab treatment in non-radiographic axial spondyloarthritis","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib193","first-page":"i52","article-title":"Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis with positive MRI of the sacroiliac joints or spine or elevated C-reactive protein at baseline","volume":"52","author":"Sieper","year":"2013","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib194","first-page":"S583","article-title":"Improvement in physical function, health-related quality of life, and work productivity with adalimumab treatment in nonradiographic axial SPA: WK-52 results from ability-1","volume":"64","author":"van der Heijde","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib195","first-page":"624","article-title":"Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis","volume":"29","author":"Kimel","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib196","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2790","article-title":"Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key20160205101913341_ref1-bib197","first-page":"1346","article-title":"Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)","volume":"35","author":"Revicki","year":"2008","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib198","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/rheumatology\/keu438","article-title":"Sustained improvement of spinal mobility, physical function, and quality of life in patients with ankylosing spondylitis: 5-year results","volume":"63","author":"van der Heijde","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib199","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1186\/ar2794","article-title":"Predictors of radiographic progression in adalimumab-treated patients with Ankylosing Spondylitis","volume":"62","author":"Maksymowych","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib200","first-page":"i18","article-title":"Relationship between bone formation in patients with ankylosing spondylitis and clinical signs and symptoms","volume":"49","author":"van der Heijde","year":"2010","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib201","doi-asserted-by":"publisher","first-page":"i56","DOI":"10.1136\/ard.2007.087270","article-title":"Improvement in long-term spinal mobility in patients with ankylosing spondylitis (AS) is sustained during up to 3 years of adalimumab treatment: 3-year atlas results","volume":"48","author":"Scott","year":"2009","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib202","doi-asserted-by":"publisher","first-page":"S767","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Effect of certolizumab pegol over 48 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"65","author":"Landewe","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib203","doi-asserted-by":"publisher","first-page":"A569","DOI":"10.1016\/j.jval.2013.08.1523","article-title":"Long-term maintenance of improvements in patient-reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 48-week results of the rapid-axspa study","volume":"16","author":"Sieper","year":"2013","journal-title":"Value Health"},{"key":"key20160205101913341_ref1-bib204","first-page":"1496","article-title":"Effect of certolizumab pegol over 48 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"41","author":"Maksymowych","year":"2014","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib205","first-page":"662","article-title":"Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept","volume":"35","author":"Boonen","year":"2008","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib206","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/art.21330","article-title":"Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy","volume":"53","author":"Davis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib207","first-page":"S642","article-title":"Safety and efficacy of etanercept in early non-radiographic axial spondyloarthritis: a randomized, double-blind, placebo-controlled trial at 24 weeks","volume":"65","author":"Dougados","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib208","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/art.20241","article-title":"Results from an open-label extension study of etanercept in ankylosing spondylitis","volume":"51","author":"Davis","year":"2004","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib209","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/annrheumdis-2013-eular.2835","article-title":"Safety and efficacy of golimumab, a human anti-TNF monoclonal antibody injected subcutaneously every 4 weeks, in Chinese patients with active ankylosing spondylitis: one-year results of a phase 3, randomized, placebo-controlled study","volume":"72","author":"Bao","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib210","first-page":"S651","article-title":"Safety and efficacy of golimumab, a human anti-tumor necrosis factor monoclonal antibody injected subcutaneously every 4 weeks, in Chinese patients with active ankylosing spondylitis: 1-year results of a phase 3, randomized, placebo-controlled study","volume":"65","author":"Bao","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib211","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/kes251","article-title":"Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)","volume":"52","author":"van der Heijde","year":"2013","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib212","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/annrheumdis-2013-eular.880","article-title":"Long-term safety and efficacy of golimumab in the treatment of ankylosing spondylitis: results through 5 years of the go-raise trial","volume":"72","author":"Deodhar","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib213","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/annrheumdis-2012-eular.2243","article-title":"The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results","volume":"71","author":"Braun","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib214","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/annrheumdis-2012-eular.1853","article-title":"Achieving ASDAS-CRP major improvement and inactive disease in patients with ankylosing spondylitis after treatment with golimumab is associated with normalized health related quality of life: two-year results from the go-raise trial","volume":"71","author":"van der Heijde","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib215","first-page":"i161","article-title":"Achieving ankylosing spondylitis disease activity score c-reactive protein major improvement and inactive disease in patients with ankylosing spondylitis after treatment with golimumab is associated with normalized health-related quality of life: 2-year results from go-raise","volume":"52","author":"van der Heijde","year":"2013","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib216","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/annrheumdis-2012-eular.2243","article-title":"The effect of anti-tumor necrosis factor therapy with golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results","volume":"15","author":"Braun","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"key20160205101913341_ref1-bib217","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of anti-tumor necrosis factor therapy with two different doses of golimumab on radiographic progression in definite ankylosing spondylitis: 4-year results","volume":"1","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib218","first-page":"1227","article-title":"Sustained clinical response with golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of a randomized, placebo-controlled study","volume":"1","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib219","first-page":"24","article-title":"Golimumab, a new, human, TNF-alpha antibody administered subcutaneously every 4 weeks, in ankylosing spondylitis: 104-week efficacy and safety results of the randomized, placebo-controlled go-raise study","volume":"39","author":"Braun","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"key20160205101913341_ref1-bib220","first-page":"152","article-title":"Golimumab, a new, human, TNF-alpha antibody administered subcutaneously every 4 weeks, in ankylosing spondylitis: 104 week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study","volume":"13","author":"Kim","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"key20160205101913341_ref1-bib221","first-page":"1259","article-title":"Golimumab, a new, human, TNF-antibody administered subcutaneously every 4 weeks, in ankylosing spondylitis (AS): 104-week efficacy and safety results of the randomized, placebo-controlled GO-RAISE study","volume":"60","author":"Braun","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib222","first-page":"618","article-title":"Golimumab, a new, human, TNF-alpha antibody administered subcutaneously every 4 weeks, in ankylosing spondylitis: 104-week efficacy and safety results of the randomized, placebo controlled GO-RAISE study","volume":"28","author":"Braun","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib223","first-page":"3326","article-title":"Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13","volume":"65","author":"Park","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib224","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/ard.2007.075879","article-title":"Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response","volume":"67","author":"Braun","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib225","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years","volume":"44","author":"Braun","year":"2005","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib226","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib227","first-page":"412","article-title":"Clinical response to long-term therapy with infliximab in patients with ankylosing spondylitis \u2013 results after 3 years","volume":"63","author":"Baraliakos","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib228","first-page":"413","article-title":"Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis (AS) after 3 years of continuous treatment with infliximab","volume":"63","author":"Baraliakos","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib229","first-page":"S172","article-title":"Two year follow up results of a controlled trial of the anti-TNF alpha antibody infliximab in active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib230","first-page":"S429","article-title":"One year results of a double-blind placebo controlled, phase-III clinical trial of infliximab in active ankylosing spondylitis","volume":"46","author":"Brandt","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib231","first-page":"672","article-title":"The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab","volume":"29","author":"Heldmann","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"key20160205101913341_ref1-bib232","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.24001","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period","volume":"59","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib233","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2748","article-title":"MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor","volume":"71","author":"Machado","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib234","first-page":"520","article-title":"European ankylosing spondylitis infliximab cohort (EASIC): long-term (5 years) efficacy of infliximab on disease activity and function: a real life experience after the end of ASSERT","volume":"60","author":"Heldmann","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key20160205101913341_ref1-bib235","first-page":"iI72","article-title":"Infliximab improves spinal mobility in patients with ankylosing spondylitis: two-year findings from the assert clinical trial","volume":"47","author":"Braun","year":"2008","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib236","first-page":"390","article-title":"Infliximab improves spinal mobility in patients with ankylosing spondylitis: two-year findings from the assert clinical trial","volume":"66","author":"Braun","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib237","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"3rd edn."},{"key":"key20160205101913341_ref1-bib238","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key20160205101913341_ref1-bib239","doi-asserted-by":"publisher","first-page":"A314","DOI":"10.1016\/j.jval.2011.08.450","article-title":"Sensitivity of PRO\u2019s to detect changes in quality of life in patients treated with a biologic agent","volume":"14","author":"Pumford","year":"2011","journal-title":"Value Health"},{"key":"key20160205101913341_ref1-bib240","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2288-11-91","article-title":"Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation","volume":"11","author":"Wade","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"key20160205101913341_ref1-bib241","doi-asserted-by":"publisher","first-page":"A306","DOI":"10.1016\/j.jval.2011.08.407","article-title":"Differences in cost-of-illness and quality of life between rheumatoid arthritis and ankylosing spondylitis in South Korea","volume":"14","author":"Lee","year":"2011","journal-title":"Value Health"},{"key":"key20160205101913341_ref1-bib242","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3346\/jkms.2014.29.2.190","article-title":"Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea","volume":"29","author":"Lee","year":"2014","journal-title":"J Korean Med Sci"},{"key":"key20160205101913341_ref1-bib243","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1524-4733.2009.00669.x","article-title":"The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost\u2013utility ratios: results across five trial-based cost-utility studies","volume":"13","author":"Joore","year":"2010","journal-title":"Value Health"},{"key":"key20160205101913341_ref1-bib244","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/art.10658","article-title":"Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial","volume":"47","author":"Van Tubergen","year":"2002","journal-title":"Arthritis Rheum-Arthritis Care Res"},{"key":"key20160205101913341_ref1-bib245","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/03009740701607224","article-title":"The cost effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data","volume":"65","author":"Kobelt","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib246","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/03009740701607224","article-title":"The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data","volume":"37","author":"Kobelt","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"key20160205101913341_ref1-bib247","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/ard.61.5.429","article-title":"Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries","volume":"61","author":"Boonen","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib248","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/ard.62.8.741","article-title":"Costs of ankylosing spondylitis in three European countries: the patient\u2019s perspective","volume":"62","author":"Boonen","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib249","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20160205101913341_ref1-bib250","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/ard.2006.060384","article-title":"How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?","volume":"66","author":"Boonen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib251","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/ard.2008.100164","article-title":"Role of contextual factors in health-related quality of life in ankylosing spondylitis","volume":"69","author":"Gordeev","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key20160205101913341_ref1-bib252","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/rheumatology\/41.12.1380","article-title":"Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness","volume":"41","author":"Haywood","year":"2002","journal-title":"Rheumatology"},{"key":"key20160205101913341_ref1-bib253","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","article-title":"Variations in population health status: results from a United Kingdom national questionnaire survey","volume":"316","author":"Kind","year":"1998","journal-title":"BMJ"},{"key":"key20160205101913341_ref1-bib254","volume-title":"A Social Tariff for EuroQol: Results from a UK General Population Survey","author":"Dolan","year":"1995"},{"key":"key20160205101913341_ref1-bib255","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N","article-title":"The time trade-off method: results from a general population study","volume":"5","author":"Dolan","year":"1996","journal-title":"Health Econ"},{"key":"key20160205101913341_ref1-bib256","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3899\/jrheum.091359","article-title":"Evaluation of ankylosing spondylitis quality of life (EASi-QoL): reliability and validity of a new patient-reported outcome measure","volume":"37","author":"Haywood","year":"2010","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib257","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3899\/jrheum.090449","article-title":"Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"37","author":"Kvamme","year":"2010","journal-title":"J Rheumatol"},{"key":"key20160205101913341_ref1-bib258","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/03009742.2010.503661","article-title":"Cost-effectiveness analyses of elective orthopaedic surgical procedures in patients with inflammatory arthropathies","volume":"40","author":"Osnes-Ringen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"key20160205101913341_ref1-bib259","doi-asserted-by":"publisher","first-page":"A667","DOI":"10.1136\/annrheumdis-2013-eular.1978","article-title":"Patients with non-as axial SPA have similar prevalence compared to as, but worse perceived health. Results from a population based study","volume":"72","author":"Lindstrom","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20090\/hta20090.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20090\/hta20090.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T08:26:21Z","timestamp":1718353581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20090\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":259,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["10.3310\/hta20090"],"URL":"https:\/\/doi.org\/10.3310\/hta20090","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}